Introduction
Community pharmacy practice-based research networks (CP PBRNs) have the potential to enhance patient care, improve medication usage including adherence, and foster collaboration among pharmacists and other healthcare providers.
1 In 2010, a CP PBRN termed the Medication Safety
Research Network of Indiana (Rx-SafeNet) 2 was launched by the Purdue College of Pharmacy to connect College faculty with practicing community pharmacists. Rx-SafeNet's mission is to improve medication safety and advance community pharmacy practice in Indiana through the conduct and dissemination of collaborative, patient-centered, practicebased research. Despite such efforts and those like it, development of new CP PBRNs has remained slow compared to development of other healthcare PBRNs. 3 Current literature to assist aspiring PBRNs focuses on progressive growth and network maturation may be thought of as occurring in a step-wise progression of four stages of development: 1) conceptualization; 4 2) implementation; 5 3) growth 6 and finally, 4) maturation. 4 Most PBRN literature has focused on conceptualization and implementation challenges; for example, Rx-SafeNet 5 and
Seston et al. 7 previously shared early experiences about laying the groundwork for their CP PBRNs, drafting policies and procedures, and completing early projects with a small number of pharmacies. However, generalizability of these findings are limited by the projects' small sample size and few participating pharmacies. 6 Further findings by Schommer provide suggestions for stimulating inter-network growth by boosting participating community pharmacies and sample size, 8 but more research is warranted to explore the proposed strategies. To address the paucity of literature regarding the challenges facing CP PBRNs during later stages of development, we are sharing the experience of growing Rx-SafeNet with specific challenges related to managing growth and sustainability. In this context, growth refers to the addition of pharmacies and pharmacist members, implementation of increasingly complex projects, and the movement toward greater external grant funding for research projects. Specifically, we are sharing techniques we have developed and utilized to overcome several challenges experienced during the growth and early maturation stages, including: 1) Increasing membership, 2) Staffing needs, 3) Revisiting policies and procedures, 4) Relationship building, 5) Developing project ideas, and 6) Achieving maturation.
Network Overview
Rx-SafeNet was launched in 2010 by the Purdue University College of Pharmacy as part of a larger initiative designed to enhance the community pharmacist's role in promoting medication safety. 5, 9 The Network includes independent, chain, and hospital/health-system outpatient community pharmacies across the state of Indiana and is led by a 4-person Executive Committee comprised of a faculty member, fellow, and two staff members. The Network is also supported by a Project Review Team (PRT), comprised of Purdue faculty who review proposed study protocols for scientific quality and feasibility. Finally, Network leadership also includes an Advisory Board that meets quarterly and shares expertise from working with other PBRNs, assists with strategic planning, and provides guidance concerning Network policies.
See Table 1 for a compilation of all challenges and solutions presented.
Challenge: Increase Membership
To increase Network membership, as described previously, 5 formal information sessions for pharmacy staff were initially held in the community to raise awareness and provide education regarding the benefits of Network membership. While these sessions were valuable and resulted in new members, we found they attracted less than 25 pharmacists and technicians total.
Solution:
To stimulate additional interest in Rx-SafeNet and achieve greater attendance at information sessions, we worked with our College's continuing education (CE) department to develop a 1 hour CE credit course for pharmacists and pharmacy technicians. This has created a "win-win" situation, as the Network receives additional support and the learners gain important exposure to community pharmacy research. In terms of student learners, projects have been tailored that usually could be completed during their one-month rotation; although, planning is critical due to the wide variance in the workload of the Network in number of submitted grant applications, complexity of applications and manuscripts, and timing of student rotations.
Challenge: Revisiting Policies and Procedures
In tandem with Network growth, it became apparent that changes to the Network's policies and procedures were required. One example of a required policy change involved the Project Review Team (PRT). The PRT members, faculty in the Department of Pharmacy Practice, felt burdened with the number of studies progressing through the Network during each successive review period. Further, they felt that submitted project protocols were written in a manner that did not provide sufficient information for review. In addition, we observed confusion with existing policy regarding the PRT members' role and in particular, whether they needed to "approve" protocols or simply offer feedback. Another example of a required policy change involved working with investigator(s) that were not Rx-SafeNet members. Specifically, it was important to ensure appropriate acknowledgment was given to Rx-SafeNet for studies that resulted in publication. Finally, a policy that we added concerned pharmacy and pharmacist confidentiality with respect to Rx-SafeNet membership.
Solution: With respect to the PRT, streamlining the workload by updating the policy was needed for the PRT to function efficiently. Thus, the PRT policy was updated to ensure that investigators submit a proposal in final form as well as an IRB application to ensure study clarity. This updated role created an avenue for PRT member compensation and provided clarity that a review, not approval, is the expectation for PRT members. To compensate the PRT members, we also developed a policy to fund attendance to one national conference per year for each member, dependent upon available funding.
With respect to investigators external to Rx-SafeNet, we have identified a need for better education. For example, early study investigators unaffiliated with the Network did not routinely adhere to our publication policy, which stipulates that investigators mention Rx-SafeNet in the methods section as well as the secondary title of a journal article, for example, "Title of Study: a study of the Medication Safety Research Network of Indiana." While we had drafted a guidance document for collaborators previously, we have been working to further emphasize its content.
With regard to our confidentiality policy, we have found that some members would rather not disclose their participation in the Network to other members, while other members are very open about their participation. Thus, we have made a blanket policy to keep all membership confidential. As such, all mass communications to Rx-SafeNet members are emailed under blinded copy, and membership status is not disclosed to anyone outside of Network/College leadership without member permission. We are currently in the process of revisiting the policy to determine if another revision is warranted to formalize members' ability to wave their confidentiality in specific circumstances, and to encourage dialogue among members for the purpose of identifying potential pitfalls upon introducing study protocols.
Challenge: Relationship Building
One of the challenges that we discovered was to find the time required for pharmacists to complete human subject protection training for studies in which a pharmacist is a coinvestigator or participating in data collection. In carrying out projects during the growth stage, we noted the importance of incentivizing members for projects requiring human subject protection training to ensure participation. Also, with regard to our Institutional Review Board (IRB), we discovered that this relationship was a challenge common to PBRNs that had to be addressed. [10] [11] [12] [13] [14] [15] In some cases, we received differing advice from the IRB when a question emerged. For example, in several studies, the question arose as to whether pharmacists and technicians were key personnel or non-key personnel on several particular projects. This issue was important because it dictated human subject protection In terms of engaging other CP PBRNs to promote Network projects, we have been successful in establishing a relationship with a CP PBRN in our region and were able to jointly participate in a project idea introduced by an outside organization. The project was conducted in both PBRNs and we plan to work on joint projects in the future. In addition, AHRQ offers a PBRN conference each year, also promoting the opportunity to meet and potentially work with other CP PBRNs and other PBRNs that may be interested in our work. As a result of attending the PBRN conference in 2014, we established a working relationship with a PBRN focused on studies to prevent drug abuse. Ultimately, our Network was written into their grant proposal which was funded, including funding for a study within our Network. In addition, an investigator from another College of Pharmacy expressed interest in utilizing Rx-SafeNet for a pilot project that was successful. Plans are currently underway to use the pilot project as preliminary work for a larger, federal application that will benefit the Network and the outside investigator.
INNOVATIONS in pharmacy

Challenge: Member Engagement
As mentioned previously, project ideas are received from academic investigators both within and outside of the College of Pharmacy, and also from Network members. Ideas from members are communicated by Site Coordinators; they are the designated contact for the participating community pharmacy in discussions with the Network, primarily the Network Manager. All of the ideas offered by the different groups propelled us into Network growth as we found that we needed to increase the number of member pharmacies to share the activities required of an increasing number of projects. In addition, it is important for Site Coordinators to remain engaged with the Network when they are not involved in a specific project.
Solution:
To ensure that projects are of interest to Site Coordinators, we established a "project idea form" for investigators and members early in our history to assess the viability of the project ideas. Individual investigators or pharmacist members are able to propose a research idea by filling out a brief 1-page project idea form located on the RxSafeNet website. 9 Examples of projects proposed have related to medication disposal, medication therapy management, health promotion, and pharmacist-provided education.
After a project idea form has been submitted to Rx-SafeNet by fax or email, Site Coordinators are polled to determine their interest in the project via email. These emails are ballots that have embedded links; the Site Coordinator can click on the embedded link to cast their vote on whether they are interested in pursuing the project. Projects are then tracked to inform Site Coordinators and the College of Pharmacy about progress on project idea generation. To date, 24 projects have been presented to Site Coordinators since inception and they voted to pursue 19 (approximately a 79% approval rate). Ten projects have been completed, 1 is in the data collection phase, and 7 have been approved for further development. Of the 7 approved for development, 1 proposal has been funded (the previously mentioned project with the drug abuse PBRN) and 6 proposals did not receive federal or foundation funding. To keep Site Coordinators engaged when they are not participating in specific projects, we include information on Network projects in our quarterly newsletter. These newsletters are emailed to each Site Coordinator, including polling results and progression of Network projects to completion. We also distribute a Project Summary report to all members upon project completion so they are aware of the project outcome. Solution: To gain experience among our members and continue to full maturation, we utilized our start-up Lilly Endowment, Inc. funding to facilitate several smaller projects since 2012. These projects have been kept purposefully small, with few study sites (5-10 or less pharmacies) and a short data collection period (typically 6 months or less). This has provided an opportunity to test Network infrastructure without requiring a large budget. However, in an effort to maintain the Network's financial sustainability, we must now decline most investigator-initiated studies that are unable to obtain funding. In other words, it is a priority to seek federal or foundation funding for all Rx-SafeNet projects. We have sought several strategies to acquire funding. For example, after competing successfully for an internal University equipment grant, we were able to purchase several tablets for use in data collection in 2014.
Finally, to better understand member needs and enhance grant writing, we briefly surveyed Network Site Coordinators in 2014 regarding preferred monetary and non-monetary compensation for project participation. The majority of Site Coordinators indicated that gift cards are the preferred method of payment on both small and larger studies. In general, we compensate $50-$75/hour (typically to the member pharmacy) for pharmacist time spent on projects. However, there are some pharmacies that cannot accept remuneration for pharmacists' and/or technicians' time on specific projects due to their own policy which prevents this. In addition, hospitality in the form of staff lunches is not allowed per specific policies at some pharmacies. This has made it difficult to incentivize pharmacies for their project participation.
Conclusion
Clearly, issues emerge with the progression of PBRN development, with each step requiring reflection to promote ongoing success and sustainability. At the same time, adjustments to Network policies and procedures may be required. As described, Rx-SafeNet has progressed through PBRN growth and is in the process of attaining early maturation on its way to full maturation. We have discovered new challenges and lessons learned. Notably, we have been successful in adding 162 pharmacies to the Network and thus are confident in our outreach strategies. As such, we continue to clarifying policies for collaborators as early as possible, anticipating this is an area for continued vigilance as the network grows.
Promoting sustainability will require a continued focus on clinician involvement in research and further emphasis on the importance of identifying appropriate compensation for clinician members. This challenge has been noted by other PBRN researchers. 16 As we continue to make strides toward full maturation, more complex studies and larger investigative teams, receiving large, federally funded studies will be critical. As Green 4 notes about where primary care
PBRNs were in 2006, it appears this is where CP PBRNs are at the present time: "These networks are now both a place and a concept. As a place, they are laboratories for surveillance and research. As a concept, they express the still unmet need for practicing clinicians to accept responsibility to improve clinical care by understanding what is happening in their practices." Full maturation is an ongoing challenge, however one that will certainly ensure the practice of pharmacy a richer experience for patients, pharmacists, and researchers. 
